We are live on ! Find out more
MGNX icon

MacroGenics

130 hedge funds and large institutions have $789M invested in MacroGenics in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

2% more funds holding

Funds holding: 127130 (+3)

2% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

1% less capital invested

Capital invested by funds: $794M → $789M (-$5M)

4.01% less ownership

Funds ownership: 91.1%87.1% (-4%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $212K

Holders
130
Holders Change
+3
Holders Change %
+2.36%
% of All Funds
2.97%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
15
Increased
43
Reduced
42
Closed
12
Calls
Puts
$212K
Net Calls
-$212K
Net Calls Change
-$312K

MGNX Hedge Fund Activity: Q3 2018 in Review

130 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q3 2018, worth a combined $789M — down 0.63% from $794M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new MGNX positions and 12 closed out — a net gain of 3 holders — while 43 added to existing stakes and 42 trimmed.

The largest buyer was BB Biotech, adding an estimated $7.03M. The largest seller was Boxer Capital, exiting entirely with an estimated $25.7M sold.

  • 130 institutional investors held MacroGenics (MGNX) as of Q3 2018, up from 127 in Q2 2018.
  • Funds reported $789M of MacroGenics stock for Q3 2018, down 0.63% quarter-over-quarter.
  • 15 funds opened new MacroGenics positions in Q3 2018 and 12 closed out, a net change of +3 holders.
  • The largest MacroGenics buyer in Q3 2018 was BB Biotech, an estimated $7.03M added.
  • The largest MacroGenics seller in Q3 2018 was Boxer Capital, an estimated $25.7M sold.

Based on aggregated 13F filings for Q3 2018.